| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 196,9 k € | +3.2% | 190,8 k € | -13.8% | 221,3 k € | -2.3% | 226,5 k € | +28.9% | 175,7 k € | +31.6% | 133,5 k € | +23.7% | 107,9 k € | +2372.8% | -4,7 k € | -519.2% | 1,1 k € | +145.6% | -2,5 k € | -181.3% | -883,5 € | -119.5% | 4,5 k € | +132.2% | -14,1 k € | |
| EBITDA | 145,7 k € | -3.7% | 151,3 k € | -18.9% | 186,5 k € | -5.5% | 197,4 k € | +27.2% | 155,1 k € | +26.0% | 123,1 k € | +24.1% | 99,2 k € | +1902.3% | -5,5 k € | -1547.9% | 380,1 € | +110.7% | -3,6 k € | -69.4% | -2,1 k € | -164.6% | 3,3 k € | +121.0% | -15,5 k € | |
| Operating profit | 91,8 k € | -1.9% | 93,6 k € | -15.1% | 110,3 k € | +7.2% | 102,8 k € | +61.3% | 63,8 k € | +88.6% | 33,8 k € | +131.1% | 14,6 k € | +361.1% | -5,6 k € | -22.2% | -4,6 k € | +47.5% | -8,7 k € | -20.1% | -7,3 k € | -282.5% | -1,9 k € | +91.5% | -22,2 k € | |
| Profit/loss | 55,2 k € | -5.5% | 58,4 k € | -3.6% | 60,6 k € | +7.6% | 56,3 k € | +42.1% | 39,6 k € | +233.5% | 11,9 k € | +733.7% | -1,9 k € | +68.2% | -5,9 k € | -26.9% | -4,7 k € | +48.2% | -9,0 k € | -16.9% | -7,7 k € | -210.6% | -2,5 k € | +89.1% | -22,7 k € | |
| Equity | 247,7 k € | -2.4% | 253,7 k € | +29.9% | 195,3 k € | +45.0% | 134,8 k € | +71.8% | 78,4 k € | +102.1% | 38,8 k € | +44.1% | 26,9 k € | -6.5% | 28,8 k € | +171.5% | -40,3 k € | -13.1% | -35,6 k € | -33.7% | -26,7 k € | -40.4% | -19,0 k € | -15.0% | -16,5 k € | |
| Total assets | 608,5 k € | -6.6% | 651,6 k € | -4.3% | 681,2 k € | -4.6% | 714,0 k € | +5.6% | 675,8 k € | -5.7% | 716,3 k € | -11.9% | 812,9 k € | +1202.5% | 62,4 k € | +6.5% | 58,6 k € | +4.0% | 56,3 k € | -2.1% | 57,5 k € | +2.7% | 56,0 k € | +26.4% | 44,3 k € | |
| Cash | 139,8 k € | -30.9% | 202,4 k € | -13.4% | 233,7 k € | +34.9% | 173,2 k € | +108.1% | 83,3 k € | +24.8% | 66,7 k € | +2.8% | 64,9 k € | +335.6% | 14,9 k € | -15.9% | 17,7 k € | +97.8% | 9,0 k € | +47.4% | 6,1 k € | -68.3% | 19,2 k € | +121.7% | 8,7 k € | |
| Debts | 357,8 k € | -10.1% | 397,9 k € | -18.1% | 485,9 k € | -16.1% | 578,9 k € | -3.1% | 597,4 k € | -11.4% | 674,1 k € | -14.2% | 786,0 k € | +2238.3% | 33,6 k € | -66.0% | 98,9 k € | +7.7% | 91,9 k € | +9.1% | 84,2 k € | +14.8% | 73,4 k € | +20.8% | 60,7 k € | |
| Staff | 1,4 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||||||||
Private limited company · Charleroi · incorporated on 23/12/2011 · 1,4 ETP
Private limited company profitable and well capitalised. Cash position declining (-30.9%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
PHARMA 2424 is a Private limited company incorporated in 2011. Its main activity is: Manufacture of pharmaceutical preparations. Its registered office is in Charleroi. It employs on average 1,4 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette